KDIGO guidelines include FILSPARI for IgA nephropathy treatment

CSL Vifor and Travere Therapeutics (NASDAQ: TVTX) announced that updated clinical practice guidelines from Kidney Disease: Improving Global Outcomes (KDIGO) include recommendations for FILSPARI (sparsentan) in treating IgA nephropathy patients at risk of progressive kidney function loss.

The 2025 KDIGO guidelines define remission of proteinuria and slowing estimated glomerular filtration rate decline as key treatment goals. The guidelines mention FILSPARI as a potential first-line approach for managing IgAN-induced nephron loss, contrasting with previous RAS inhibitor-first approaches.

The guidelines highlight FILSPARI as the only therapy with proven efficacy compared to optimized RAS inhibitors in clinical trials. The PROTECT study, which enrolled more patients than all prior RAS inhibitor trials combined, demonstrated FILSPARI's effectiveness in reducing proteinuria by 49.8% compared to 15.1% for irbesartan after 36 weeks.

"The updated KDIGO guidance represents an important step forward for the IgA Nephropathy community," said Prof. Dr. med. Jürgen Floege from University Hospital, RWTH Aachen, Germany.

FILSPARI is approved in the United States and Europe for slowing kidney function decline in adults with primary IgA nephropathy. The drug has been launched in Germany, Austria, Switzerland, Luxembourg and the UK in addition to the U.S.

IgA nephropathy affects an estimated 150,000 people in the United States and is the most common type of primary glomerulonephritis worldwide. The disease is characterized by buildup of immunoglobulin A protein in the kidneys, leading to blood and protein in urine and progressive kidney function loss.

The updated guidelines represent a focused update of the KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases and will be published as a supplement to the Official Journal of the International Society for Nephrology.

You May Also Be Interested In